



Immune Design
 Investor Relations Department
 Immune Design Corp. Attn:
 Accounts Payab
 601 Gateway Blvd. Suite 250
 South San Francisco, CA 94080
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

| | |
|---------------|--|
| Last Trade: | 10.50 |
| Trade Time: | 4:00 PM ET Sep 22, 2017 |
| Change: | 0.15 ↑ (+1.449%) |
| Day Range | 9.80 - 10.50 |
| 52-Week Range | 4.50 - 13.05 |
| Volume | 85,138 |

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 8, 2017
[New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response](#)
- Sep 1, 2017
[Immune Design to Present at Upcoming Investor Conferences in September](#)
- Aug 30, 2017
[Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress](#)
- Aug 2, 2017
[Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)
- Jul 26, 2017
[Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update](#)

Upcoming Events [\[View all \]](#)

- Sep 28, 2017 10:30 AM ET
[Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)
- Financials** [\[View all \]](#)
- [Second Quarter Financial Results](#)
- Mar 7, 2017
[Annual Report \(10-K\)](#)
- Apr 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016
[Quarterly Report \(10-Q\)](#)